According to Zacks, “EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus. “
Separately, Roth Capital downgraded shares of EnteroMedics from a buy rating to a neutral rating and set a $3.00 target price for the company. in a research note on Thursday, June 9th.
EnteroMedics (NASDAQ:ETRM) opened at 0.115 on Wednesday. The stock’s market cap is $3.14 million. EnteroMedics has a 1-year low of $0.11 and a 1-year high of $4.95. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $0.43.
EnteroMedics (NASDAQ:ETRM) last posted its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.26. EnteroMedics had a negative net margin of 4,157.93% and a negative return on equity of 1,361.34%. On average, equities analysts anticipate that EnteroMedics will post ($2.37) earnings per share for the current year.
A hedge fund recently bought a new stake in EnteroMedics stock. Hudson Bay Capital Management LP acquired a new stake in shares of EnteroMedics Inc. (NASDAQ:ETRM) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 204,836 shares of the medical device company’s stock, valued at approximately $198,000. Hudson Bay Capital Management LP owned about 2.88% of EnteroMedics as of its most recent filing with the SEC. 5.82% of the stock is owned by institutional investors and hedge funds.
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.